Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2835)	6/16/2010 11:47:50 AM
From: Jibacoa	1 Recommendation Respond to of 3722

IMMU is up 6.69% on volume about 0.75x its ADV bigcharts.marketwatch.com It announced that its epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe SLE. The data was presented at the European League Against Rheumatism meeting in Rome from the PIIb study, EMBLEM, and suggest promising results of epratuzumab in patients with SLE. The primary efficacy measure in EMBLEM was a combined response index endpoint including several indices of SLE disease activity. In the EMBLE study, combined responder index rates were numerically superior in all epratuzumab groups than in the placebo group. Epratuzumab which is a humanized monoclonal antibody targeting CD22 and modulating B-cell activity, was associated with a similar incidence of serious adverse events (including infections) and infusion reactions as the group receiving placebo. Although the exact role of CD22 is not fully understood, it is considered to be a regulator of B cell function and B-cells are known to contribute to SLE by producing autoantibodies resulting in inflammation and tissue damage. As previously mentioned, the stock needs to close above the resistance at the $4 level.<g> As mentioned, the ACTAY is $6.50 And it seems that with some good news the stock could get to the $7 level in spite of the fact that the "analysts" are expecting for IMMU to report again on the red in 2011.<g> bigcharts.marketwatch.com Bernard